Construct Validity Supports Use of a Novel, Tablet-Based Neurocognitive Assessment for Adolescents and Young Adults Affected by Perinatal HIV from Vulnerable Communities in the United States.

Construct validity of novel tablet-based neurocognitive tests (in the NeuroScreen app) measuring processing speed, working memory, and executive functioning in adolescents and young adults (AYA) living with perinatally-acquired HIV (PHIV) and perinatal HIV-exposure without infection (PHEU) was exami...

Descripción completa

Detalles Bibliográficos
Publicado en:	AIDS & Behavior Vol. 25; no. 4; pp. 1185 - 1192
Autores principales:	Robbins, R. N., Kluisza, L., Liu, J., Santoro, A. F., Raymond, J., Ngyuen, N., Espinel, S., Siegel, E., Dolezal, C., Wiznia, A., Abrams, E. J., Mellins, C. A.
Formato:	research tables/charts Journal Article
Publicado:	Springer Nature Apr2021
Acceso en línea:	Ver este registro en EBSCOhost

Descripción
Sumario:	Construct validity of novel tablet-based neurocognitive tests (in the NeuroScreen app) measuring processing speed, working memory, and executive functioning in adolescents and young adults (AYA) living with perinatally-acquired HIV (PHIV) and perinatal HIV-exposure without infection (PHEU) was examined. Sixty-two AYA (33 PHIV, 29 PHEU) were recruited from an ongoing longitudinal study (CASAH) in New York City. Medium to large and statistically significant correlations were found between NeuroScreen and gold standard, paper-and-pencil tests of processing speed, working memory, and executive functioning. Results provide partial support for NeuroScreen as an alternative to cumbersome paper-and-pencil tests for assessing neurocognition among HIV-affected AYA.